15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Artelo Biosciences Inc, 0 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $18.00 to $18.00, so the covering firms are broadly aligned. The average target of $18.00 sits 2408% above the current $0.72. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Hold
Strong Buy00%
Buy00%
Hold2100%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Artelo Biosciences Inc.
As of Aug, 0 of 2 firms rate ARTL a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ARTL EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect Artelo Biosciences Inc to earn — a share (range — – —), versus — a year earlier. , growing to $-5.28 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Artelo Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARTL.
#1
Jason Kolbert
D. Boral Capital · Rank #407
Hold
No targeton ARTL
Overall win rate
22%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #417
Hold
No targeton ARTL
Overall win rate
33%
+ Follow
#3
Vernon Bernardino
HC Wainwright & Co. · Rank #440
Buy
$5.00+596.7% to target
Overall win rate
14%
+ Follow
#4
Jason Kolbert
EF Hutton
Buy
$6.00+736.0% to target
Coverage
—
+ Follow
ARTL stock forecast FAQ
Is ARTL stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 2 analyst ratings, 0 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ARTL?+
2 analysts have an active rating on Artelo Biosciences Inc.
Who is the most accurate analyst covering ARTL?+
Among analysts who currently cover ARTL, Jason Kolbert of D. Boral Capital has the strongest overall Quantellect track record (Rank #407). Their current call is Hold.
What is Artelo Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at —, rising to $-5.28 the following year.
How much revenue is Artelo Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ARTL lately?+
As of Aug, 0 of 2 firms rate ARTL a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
